A phase II, multicenter, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid, CC-5013) in subjects with relapsed or refractory indolent non-Hodgkin's lymphoma

Trial Profile

A phase II, multicenter, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid, CC-5013) in subjects with relapsed or refractory indolent non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2009 Final results presented at ASCO 2009.
    • 05 Dec 2006 Status change
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top